logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

XIAO NOODLES (02408) repurchased 98,500 shares for HKD 405,400 on October 9.

date
17:02 09/10/2026
avatar
GMT Eight
XIAO NOODLES (02408) announced that on October 9, 2026, it repurchased 98,500 shares for HKD 405,400.
XIAO NOODLES (02408) announced that on October 9, 2026, it repurchased 98,500 shares for HKD 405,400.
Related Articles
HK Stock
ZHENRO PPT (06158) accumulated contracted sales for the first nine months amounted to approximately RMB 3.101 billion, a year-on-year decrease of 5.69%.
HK Stock
CHAOJU EYE CARE (02219) spent HKD 452,200 to repurchase 189,500 shares on October 9.
HK Stock
Shanghai Pharmaceuticals Holding (02607): Clevidipine Emulsion Injection Approved for Production
ZHENRO PPT (06158) accumulated contracted sales for the first nine months amounted to approximately RMB 3.101 billion, a year-on-year decrease of 5.69%.
HK Stock
CHAOJU EYE CARE (02219) spent HKD 452,200 to repurchase 189,500 shares on October 9.
HK Stock
Shanghai Pharmaceuticals Holding (02607): Clevidipine Emulsion Injection Approved for Production
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.